Pacific Biosciences
PACB
109 hedge funds and large institutions have $206M invested in Pacific Biosciences in 2017 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
11% more funds holding
Funds holding: 98 → 109 (+11)
6% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 31
3.92% less ownership
Funds ownership: 70.91% → 66.99% (-3.9%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
52% less capital invested
Capital invested by funds: $430M → $206M (-$225M)
96% less call options, than puts
Call options by funds: $42K | Put options by funds: $1.06M
Top Buyers
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.79M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$2.17M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.23M |
| 4 |
SIM
Spark Investment Management
New York
|
+$935K |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
+$728K |
Top Sellers
| 1 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$4.32M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.28M |
| 3 |
BlackRock
New York
|
-$4.27M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.52M |
| 5 |
SFM
Soros Fund Management
New York
|
-$3.52M |
PACB Hedge Fund Activity: Q4 2017 in Review
109 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2017, worth a combined $206M — down 52% from $430M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PACB positions and 13 closed out — a net gain of 12 holders — while 33 added to existing stakes and 31 trimmed.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $2.79M. The largest seller was Raging Capital Management, cutting an estimated $4.32M.
- 109 institutional investors held Pacific Biosciences (PACB) as of Q4 2017, up from 98 in Q3 2017.
- Funds reported $206M of Pacific Biosciences stock for Q4 2017, down 52% quarter-over-quarter.
- 25 funds opened new Pacific Biosciences positions in Q4 2017 and 13 closed out, a net change of +12 holders.
- The largest Pacific Biosciences buyer in Q4 2017 was ArrowMark Colorado Holdings, an estimated $2.79M added.
- The largest Pacific Biosciences seller in Q4 2017 was Raging Capital Management, an estimated $4.32M sold.
Based on aggregated 13F filings for Q4 2017.